about
Zika virus infection in pregnant women in Barcelona, SpainTransmission of Tropical and Geographically Restricted Infections during Solid-Organ TransplantationTrends in Transmission of Drug Resistance and Prevalence of Non-B Subtypes in Patients with Acute or Recent HIV-1 Infection in Barcelona in the Last 16 Years (1997-2012)Incidence of respiratory viruses in Peruvian children with acute respiratory infections.Influenza infection in the intensive care unit: Four years after the 2009 pandemic.No Major Host Genetic Risk Factor Contributed to A(H1N1)2009 Influenza SeverityTh1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza.Double (V27A/S31N) mutant 2009 pandemic influenza A (H1N1) virus isolated from adamantane non-treated inmunocompetent child.Economic Evaluation of Health Services Costs During Pandemic Influenza A (H1N1) Pdm09 Infection in Pregnant and Non-Pregnant Women in Spain.Host adaptive immunity deficiency in severe pandemic influenza.Differences in sentinel influenza confirmed incidence rates and clinical presentation of influenza virus: 2008-09 seasonal vs 2009-10 pandemic influenza.[Characteristics of cases hospitalized for severe pandemic (H1N1) 2009 in Catalonia].Pandemic influenza A(H1N1) outbreak among a group of medical students who traveled to the Dominican Republic.Prognosis of hospitalized patients with 2009 H1N1 influenza in Spain: influence of neuraminidase inhibitors.Influenza A(H1N1)pdm09: beyond the pandemic.Benefit of conjugate pneumococcal vaccination in preventing influenza hospitalization in children: a case-control study.Predictive factors of severe multilobar pneumonia and shock in patients with influenza.Effectiveness of vaccination with 23-valent pneumococcal polysaccharide vaccine in preventing hospitalization with laboratory confirmed influenza during the 2009-2010 and 2010-2011 seasons.Different prognosis in hospitalized patients with influenza one season after the pandemic H1N1 influenza of 2009-2010 in Spain.Immunohistochemically proven cytomegalovirus end-organ disease in solid organ transplant patients: clinical features and usefulness of conventional diagnostic tests.Pulmonary infiltrates in immunosuppressed patients: analysis of a diagnostic protocol.Pulmonary infiltrates in non-HIV immunocompromised patients: a diagnostic approach using non-invasive and bronchoscopic procedures.Structured Treatment Interruptions and Low Doses of IL-2 in Patients with Primary HIV Infection. Inflammatory, Virological and Immunological Outcomes.Immunogenicity and acceptance of influenza A (H1N1) vaccine in a cohort of chronic hepatitis C patients receiving pegylated-interferon treatmentInfluence of episodes of intermittent viremia ("blips") on immune responses and viral load rebound in successfully treated HIV-infected patients.Risk factors and effectiveness of preventive measures against influenza in the community.Risk of selecting de novo drug-resistance mutations during structured treatment interruptions in patients with chronic HIV infection.Incidence of respiratory viruses among travelers with a febrile syndrome returning from tropical and subtropical areas.Molecular epidemiology and molecular characterization of respiratory syncytial viruses at a tertiary care university hospital in Catalonia (Spain) during the 2013-2014 season.Dicrocoelium dendriticum: An Unusual Parasitological Diagnosis in a Reference International Health Unit.Serodiscordance in chronic Chagas disease diagnosis: a real problem in non-endemic countries.A molecular epidemiological study of human parainfluenza virus type 3 at a tertiary university hospital during 2013-2015 in Catalonia, Spain.Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.Persistence of yellow fever vaccine RNA in urine.Assessment of a Novel Automatic Real-Time PCR Assay on the Cobas 4800 Analyzer as a Screening Platform for Hepatitis C Virus Genotyping in Clinical Practice: Comparison with Massive Sequencing.Pharmacokinetics and pharmacodynamics of low dose mycophenolate mofetil in HIV-infected patients treated with abacavir, efavirenz and nelfinavir.A prospective survey of human herpesvirus-6 primary infection in solid organ transplant recipients.Effectiveness of virosomal subunit influenza vaccine in preventing influenza-related illnesses and its social and economic consequences in children aged 3-14 years: a prospective cohort study.Infection with human herpesvirus 6 after kidney-pancreas transplant.Effect of mycophenolate mofetil on immune response and plasma and lymphatic tissue viral load during and after interruption of highly active antiretroviral therapy for patients with chronic HIV infection: a randomized pilot study.
P50
Q24083063-3C598237-0A9C-405D-AC8C-FCBACC8487F1Q27485255-72074D5D-5AE7-4EF3-AE93-EF7622AACD6DQ28547790-A9731007-BCF6-4F50-8A9A-43277BFA2522Q30372804-38759EEE-33CF-43AF-8511-031DE4FE203DQ30375092-9C712CD7-6D46-4CA1-BA3A-B16A571A4765Q30379232-A45F850B-EDA9-4BB5-AD9B-962AFB4BF6D7Q30383368-6BED872A-E1A4-4369-828E-621F6F787C53Q30386648-693B5880-85EA-44F8-8559-87577A54F2E0Q30388833-71E02CF9-AFB4-4143-9DC0-86D70A6F3B1DQ30393612-03584D0E-7FB7-4B6C-9B0D-511F6D3E90E1Q30399220-A0485A60-1EDD-4A32-ABE7-EF84E3517A9CQ30404759-B9E14F82-7A26-4210-B1CF-7870D5671266Q30411378-C8145CD8-E468-46F3-85D4-44BA5A10F0E5Q30414878-478A7EBA-4613-4A1F-8910-B9F990CC2731Q30423112-B2DD0EB8-7937-4F19-A6A1-9DF57D9EC540Q30426179-526AF36A-9232-4C22-BF10-414B2FF9266EQ30427721-B52170BB-C520-4C2C-9AD1-18DB88C931A0Q30429085-1648A413-FA08-4640-B6EC-019D8ECB398BQ30430185-86C1D686-7EFF-4F63-9796-C440101CE776Q33375299-B447B31D-174A-4FD1-8372-411184378AACQ34194089-8E4F3374-6CC6-45E6-BB97-A0FE4F3CB664Q35534465-983E7912-E238-43DC-8F26-44ECCE525CDAQ35862206-DD4F8931-BBC7-4811-9205-360FE3624F8FQ36384717-7DC473AB-F58B-49A1-987C-C953D91EEB22Q36509570-DD3115D8-9BB3-47C6-BAF2-84F5B31526DAQ37998104-7485D20D-0593-4AF9-9755-85253B0E53B6Q38441406-EB34A3E1-3659-4735-AC7F-C4CCB65A70ADQ38930749-11F755DB-B8E8-4674-B875-CD336CD4B44DQ39018825-64C59F02-B474-49AE-90E8-9594D0AF3517Q39147351-07B6DA91-F3BC-4070-BDFF-BD128AA68D36Q39275725-F7FA2935-E96D-415B-B4D7-E0B7BD6EF695Q39490644-25960B3E-3283-4C61-A44B-32EE07305023Q40174400-1F717BB8-4EB6-45FF-BBB8-D90693191A84Q40331643-3886FE18-B084-4878-A087-B9F8DE7C9753Q40419604-A9E5F06B-393C-4EB8-B594-680915943B63Q40426684-3757E3CA-80F9-4F29-9097-DB9A2F15FD24Q40467555-67EC81FE-C3A7-4786-9BC7-CAACD50047F9Q40474518-F7AB228A-C93B-4600-92E4-C226E266421BQ40531969-46FF68E6-457A-435F-B639-01AA7DDF79F8Q40542223-2C34B8D3-F83E-45AE-9491-EE77323E9C17
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Pumarola T
@ast
Pumarola T
@es
Pumarola T
@sl
Tomàs Pumarola Suñe
@en
Tomàs Pumarola Suñe
@nl
type
label
Pumarola T
@ast
Pumarola T
@es
Pumarola T
@sl
Tomàs Pumarola Suñe
@en
Tomàs Pumarola Suñe
@nl
altLabel
Pumarola Sune T
@en
Pumarola T
@en
Sune TP
@en
prefLabel
Pumarola T
@ast
Pumarola T
@es
Pumarola T
@sl
Tomàs Pumarola Suñe
@en
Tomàs Pumarola Suñe
@nl
P1053
F-7583-2017
P106
P1153
7003647481
P31
P3829
P496
0000-0002-5171-7461